Principle
Adding salespeople is the most common response to a revenue shortfall and one of the least examined. It is fast, visible, easy to authorise, and it substitutes a capacity solution for a diagnosis that has not been performed, which means it works only in the specific case where capacity was actually the constraint.
Behaviour
A commercial organisation misses its number. The available explanations are numerous and mostly uncomfortable: qualification discipline has degraded, the management layer cannot coach, the ICP has drifted, the competitive position has weakened, the product no longer differentiates. Each of these requires investigation, produces an identifiable owner, and takes several quarters to remediate.
Hiring more salespeople requires none of that. It has an immediate, demonstrable action associated with it, it can be authorised in a single meeting, and it postpones the diagnostic conversation by the length of a hiring and ramp cycle, which is typically nine to twelve months. By the time the new cohort has failed to close the gap, the original question has lost its urgency and the composition of the leadership team has frequently changed.
The tell is a headcount plan that is not accompanied by an explicit statement of what constraint the headcount is intended to relieve. Where an organisation cannot articulate why capacity rather than capability is the binding constraint, it has not concluded that capacity is the constraint. It has declined to ask.
It works only in the specific case where capacity was actually the constraint, and nobody checked whether it was.
Evidence
Examine attainment distribution before proposing to expand. If the existing team's median attainment is materially below quota, capacity is not the binding constraint. Adding more reps to a system in which most reps cannot hit their number produces more reps who cannot hit their number, at proportionally increased cost.
Calculate the marginal productivity of the last three hiring cohorts. Where each successive cohort has delivered less revenue per head than its predecessor, the organisation has been substituting headcount for diagnosis for some time, and the substitution is producing diminishing returns exactly as it should.
Ask what specifically will be different for the incoming cohort. If the answer describes no change to onboarding, management, territory design, or qualification standards, the new hires will encounter precisely the conditions that produced the current team's attainment, and there is no reason to expect a different result.
Psychology
Headcount is legible to a board in a way that capability is not. A hiring plan has numbers, dates, and a cost that can be approved. A statement that the management layer needs eighteen months of development has no comparable structure and reads, to an impatient board, as an absence of a plan rather than the presence of a difficult one.
The individual incentive compounds this. A leader who requests headcount and misses is seen to have been under-resourced. A leader who declines headcount, commits to fixing capability, and misses has no such defence. The safest position for any commercial leader under pressure is to have asked for more people and been given fewer.
Commercial Risk
A growth plan built on headcount expansion, in an organisation where median attainment is below quota, is a plan to multiply an existing dysfunction. The revenue does not arrive, the cost does, and the resulting margin compression is attributed to investment in growth rather than to the misdiagnosis that produced it.
For an acquirer this is among the most expensive errors available, because it is authorised early, consumes capital continuously, and produces its evidence of failure only after twelve months, by which point the headcount is in place, the cost base has risen permanently, and reversing it requires a reduction that carries its own significant commercial and cultural cost.
The discipline required is modest and almost never imposed. Before approving any commercial headcount expansion, require a written statement of the constraint the headcount relieves and the evidence establishing that capacity rather than capability is binding. Where that statement cannot be produced, the expansion is not a growth investment. It is a deferral of a diagnosis, priced as though it were a growth investment.
Investment Committee Note